Replies to post #509224 on NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

But yet OS data was confounded during the trial. But evidently some investors may not have read NWBO's SEC 10K:
"Under the Protocol the primary endpoint was progression free survival, or PFS, and the secondary endpoint was overall survival, or OS. Both of these endpoints were confounded: the PFS endpoint by pseudo-progression, and the OS endpoint by the “crossover” provision in the trial design, which allowed all of the patients in the trial to cross over to DCVax-L treatment after tumor recurrence (while remaining blinded as to which treatment they received before tumor recurrence)."